Oxford Nutrascience Share Discussion Threads

[oakville] 10/2/2011 14:22

The University of Toronto has a keen interest here and reckon its winner...

[oakville] 10/2/2011 14:21

Exclusive License of Drug Delivery Technology from The University of
Oxford Nutrascience Group plc ("Oxford Nutrascience" or "the Company") announces that it has signed a worldwide exclusive licensing agreement with Isis Innovation Limited, the technology transfer company wholly-owned by the University of Oxford, to develop and commercialise products utilizing a novel drug delivery technology.
The drug delivery technology, which has been developed by Professor Dermot O'Hare and his research group at the University of Oxford's world renowned chemistry department, provides for outstanding taste masking, enhanced drug stability and potential for tuneable drug release properties.
Very significantly, the technology is applicable to a broad range of pharmaceuticals including major drug categories such as NSAIDS (Non-steroidal Anti-inflammatory drugs) and statins.
Recently Oxford Nutrascience has been developing taste masking for ibuprofen, a popular pain relief drug that is available over the counter (OTC), using ISIS Innovation's drug delivery technology.
The Company has recently established proof of concept for the taste masking of ibuprofen, which has removed the typical burning sensation on the throat. Following the signing of the licence with Isis Innovation Limited, Oxford Nutrascience is now proceeding to develop "no burn" chewable and liquid ibuprofen products which it intends to commercialise via the OTC and prescription markets.
ISIS Innovation's drug delivery technology is currently protected by a patent granted in the UK, Germany and France and an application has been made for the US. The Company is sponsoring research at The University of Oxford and is looking to file further patent applications during 2011.
Marcelo Bravo, Executive Chairman and Chief Technology Officer commented
"Licensing this technology from a strong academic partner such as the University of Oxford gives Oxford Nutrascience significant firepower to innovate and extend the lifecycle of existing branded generic medicines and soon to be off patent API's.
"The superior taste masking of ibuprofen and ease of formulation delivered by Isis Innovation's drug delivery technology will enable us to develop next generation ibuprofen products for markets worldwide."

RNS from last week !

[oakville] 10/2/2011 14:05

I will let you know how my meeting went tomorrow..

[oakville] 10/2/2011 13:56

2 new licenses due within the next 4 weeks.

[oakville] 10/2/2011 13:53

Don't say i didn't tell you !!!

[oakville] 10/2/2011 11:57

Good call......... Lets get this show on the road !!

[regandjess] 10/2/2011 11:41

New here.is it time this BB had a new header????????

[oakville] 10/2/2011 11:16

I was tipped a wink on this from a friend at UOT ( University of Toronto )

[pre] 10/2/2011 10:11

offer creeping up...150k sell vs 110 buy....looks set for move up....extract from latest licensing deal, which has significant market worldwide imo:


'...Very significantly, the technology is applicable to a broad range of pharmaceuticals including major drug categories such as NSAIDS (Non-steroidal Anti-inflammatory drugs) and statins...'

[oakville] 10/2/2011 08:16

The drug delivery technology, which has been developed by Professor Dermot O'Hare and his research group at the University of Oxford's world renowned chemistry department, provides for outstanding taste masking, enhanced drug stability and potential for tuneable drug release properties.

[oakville] 09/2/2011 20:34

Exclusive License of Drug Delivery Technology from The University of Oxford

Oxford Nutrascience Group plc ("Oxford Nutrascience" or "the Company") announces that it has signed a worldwide exclusive licensing agreement with Isis Innovation Limited, the technology transfer company wholly-owned by the University of Oxford, to develop and commercialise products utilizing a novel drug delivery technology.

The drug delivery technology, which has been developed by Professor Dermot O'Hare and his research group at the University of Oxford's world renowned chemistry department, provides for outstanding taste masking, enhanced drug stability and potential for tuneable drug release properties.

Very significantly, the technology is applicable to a broad range of pharmaceuticals including major drug categories such as NSAIDS (Non-steroidal Anti-inflammatory drugs) and statins.

Recently Oxford Nutrascience has been developing taste masking for ibuprofen, a popular pain relief drug that is available over the counter (OTC), using ISIS Innovation's drug delivery technology.

The Company has recently established proof of concept for the taste masking of ibuprofen, which has removed the typical burning sensation on the throat. Following the signing of the licence with Isis Innovation Limited, Oxford Nutrascience is now proceeding to develop "no burn" chewable and liquid ibuprofen products which it intends to commercialise via the OTC and prescription markets.

ISIS Innovation's drug delivery technology is currently protected by a patent granted in the UK, Germany and France and an application has been made for the US. The Company is sponsoring research at The University of Oxford and is looking to file further patent applications during 2011.

Marcelo Bravo, Executive Chairman and Chief Technology Officer commented

"Licensing this technology from a strong academic partner such as the University of Oxford gives Oxford Nutrascience significant firepower to innovate and extend the lifecycle of existing branded generic medicines and soon to be off patent API's.

"The superior taste masking of ibuprofen and ease of formulation delivered by Isis Innovation's drug delivery technology will enable us to develop next generation ibuprofen products for markets worldwide."

[oakville] 09/2/2011 19:42

Interesting.

[pre] 02/2/2011 09:20

licensing worldwide agreement rns out today!!! looks like its under the radar and not yet been noticed...

[energyi] 22/10/2006 15:41

1. JUDGMENT:Oei Hong Leong V Ban Song Long David and others - November 10, 2004
business-times.asia1.com.sg/story/0,4567,135298,00.html?
Published on: 11/10/2004 Last Visited: 11/11/2004

2 The first defendant ("David Ban") is a director with an indirect financial interest in the second defendant, 98 Holdings Pte Ltd ("98 Holdings"), which owns or controls some 51.23% of the share capital of NatSteel Ltd ("NatSteel"). On 25 January 2003, he was appointed a director of NatSteel and he has acted at all material times as one of four nominees of 98 Holdings on the board of directors of NatSteel.

3 At the material time, 98 Holdings was a consortium comprising Excel Partners Pte Ltd ("Excel"), Tazwell Pte Limited ("Tazwell") and two private equity funds, Standard Chartered Private Equity Limited and Vallance Resources Limited. Excel was and is the company of a prominent Malaysian businessman, Datuk Ong Beng Seng ("Datuk Ong") and his relatives, including David Ban.
...
5 The plaintiff's claim against the defendants is for damages suffered as a result of the publication of certain alleged defamatory words attributed to David Ban in the BT article of 4 June 2003.
...
David Ban, a NatSteel director representing hotelier Ong Beng Seng's interests, told BT that attempts by the company's legal counsel, Allen & Gledhill, to sound out Mr Oei's intentions have come to naught.

"He's playing his card close to his chest. His lawyer said the client is away," Mr Ban said of Mr Oei.
...
Mr Ban, however, feels that Mr Gerald is "playing to the gallery".
...
Mr Ban said Mr Oei's opposition isn't rational.
...
There was no dispute that the words attributed to David Ban were spoken by him.
...
7 It was the plaintiff's case that Catherine Ong falsely and maliciously caused the words in question to be published and that David Ban, 98 Holdings and SPH falsely caused the same words concerning the plaintiff to be written and published.
...
The plaintiff alleged that the statements made by David Ban were timed and intended to cause him maximum damage and embarrassment in the eyes of the influential readership of the BT which included the minority shareholders of NatSteel who were due to attend the adjourned extraordinary general meeting ("EGM") on 4 June 2003. He alleged that David Ban was both speaking in his own capacity as well as in the capacity of spokesman for

Oei Hong Leong v Ban. Song Long David,2004, SGHC 253

98 Holdings. The plaintiff also alleged that SPH must bear responsibility for Catherine Ong's acts and that SPH had readily provided her with the opportunity to defame him. He also asserted that this was not the first time that SPH and Catherine Ong had libelled him during the battle for control of NatSteel but they had the grace to publish an apology on the previous occasions.

8 The plaintiff claimed that the words in issue caused him considerable distress and injured his dignity, character and reputation. On 5 June 2003, his former solicitors, M/s Rajah & Tann, sent letters to David Ban and to SPH demanding that they retract the allegedly defamatory statements made in the BT article of 4 June 2003, apologise and pay him damages and legal costs.
...
On 2 November 2002, the BT reported that David Ban had demanded that the plaintiff declare his intentions, stating that "the time has come for him to declare his intentions - now, today, not tomorrow".
...
After the close of the general offer on 24 January 2003, four nominees of 98 Holdings, including David Ban, were appointed to the board of NatSteel. Together with Ang, who had aligned himself with 98 Holdings by virtue of a participation agreement, 98 Holdings effectively controlled NatSteel's board of eight directors. Ang, David Ban and another of 98 Holdings' nominees formed the executive committee of the board.
...
The BT article in question identified David Ban as "a NatSteel director representing hotelier Ong Beng Seng's interests". Further, in an earlier article in the BT of 5 October 2002, David Ban was described by Catherine Ong as "Mr Ong's trusted lieutenant", a description which accurately reflected the relationship between David Ban and Datuk Ong. Further, in an earlier article in the BT of 5 October 2002, David Ban was described by Catherine Ong as "Mr Ong's trusted lieutenant", a description which accurately reflected the relationship between David Ban and Datuk Ong.
...
43 Both 98 Holdings and David Ban pleaded that David Ban was speaking in his capacity as a director of NatSteel when he uttered the allegedly defamatory words.
...
His actions in purchasing NatSteel's shares must have caused considerable annoyance and resentment in 98 Holdings, its shareholders and its representatives, which included David Ban, as they resulted in 98 Holdings having to pay a lot more for its controlling stake in NatSteel. The defendants thereafter resolved to adopt a course of action which they knew or ought to have known would antagonise him. When the linkage strategy was exposed, David Ban, on behalf of 98 Holdings, used the opportunity when speaking to Catherine Ong to defame the plaintiff.

...more:

[energyi] 22/10/2006 15:36

At the time when Tata Steel had its eye on NatSteel, the latter had just completed a new shareholder structure some 18 months previously when 98 Holdings paid S$770 million (US$437.5 million) in taking up 51.23% of the company. 98 Holdings enlisted two private equity investor groups, GEMS Ltd. and Standard Chartered Private Equity ('consortium') as its shareholders. It is understood the combined payment made by the consortium in this deal was in the vicinity of US$35 million.

In August 2004, Tata Steel made it known that the acquisition of the core assets of NatSteel would mean a "significant" step in its quest to enter the global playing field. In acquiring NatSteel's mills, it would add an additional 2 million tonnes to its domestic capacity of 7.5 million tonnes.

To shareholders of NatSteel, Tata Steel's offer was attractive and came at a time when the new shareholders of NatSteel were unable to lift the company's profit margin, after having been in the driver's seat for nearly 18 months. In the first half of 2004, NatSteel's profit from operations declined by 3% to S$21.8 million.

In a cash payment that amounted to S$486.4 million, Tata Steel took over NatSteel's principal source of income, the still mills in Singapore, China, Malaysia, Vietnam, the Philippines, Thailand and Australia. Together, these operations accounted for some 82% of NatSteel's 2003 revenue, 47% of pretax profit and half of the net asset value. NatSteel's shareholders were left with its non-steel businesses, which included petro-chemicals, engineering and construction products, as well as property and investment businesses.

For private equity investors, the investment in NatSteel has been a rewarding venture. In the first year since taking over the boardroom of NatSteel, the company paid a special dividend of S$0.55 per share. A portion of the net proceeds coming from Tata Steel, after a debt payment of approximately S$20 million, were distributed to NatSteel shareholders.

According to GEMS, it has tripled its invested capital in NatSteel, recording an impressive internal rate of return of 50%. It would be questionable whether such an impressive return could be achieved without Tata Steel's S$486.4 million cash payment.

...more:

[energyi] 22/10/2006 11:41

A 'trial' holiday - July 14, 2004
business-times.asia1.com.sg/sub/premiumstory/0,4574,122462,00.html?
Published on: 7/14/2004 Last Visited: 7/14/2004

A BT reporter covering Mr Oei's defamation suit against four parties including Ong Beng Seng's 98 Holdings and its director David Ban got a phone call from a woman in Hong Kong who said she would like to attend the hearing in Singapore. Asked why, the woman said she is an investor in Mr Oei's Hong Kong-listed company and she is on her way to Singapore for a holiday anyway.